Vaccine to Target Brachyury for Oncology is under clinical development by Bavarian Nordic and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Vaccine to Target Brachyury for Oncology’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Vaccine to Target Brachyury for Oncology Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Vaccine to Target Brachyury for Oncology overview

MVA-BN brachyury is under development for the treatment of solid tumors including non-small cell lung cancer, small cell lung cancer, metastatic chordoma, metastatic breast cancer, metastatic ovarian cancer, ER-/PR-/HER2+ breast cancer, metastatic colorectal cancer, triple-negative breast cancer, metastatic castrate-resistant prostate cancer, metastatic pancreatic cancer, bile duct cancer (Cholangiocarcinoma), metastatic hepatocellular cancer, Merkel cell carcinoma, metastatic bladder cancer, metastatic kidney cancer and lung cancer. It is administered through intravenous, subcutaneous and intratumor route. The therapeutic candidate consists of a primer (MVA-BN) and a booster dose (fowlpox), which have been modified to express brachyury and to encode three costimulatory molecules, known as TRICOM. It is developed based on MVA-BN, a recombinant poxvirus vector-vaccine platform technology, and TRICOM technology.

Bavarian Nordic overview

Bavarian Nordic is a vaccine company that develops, manufactures and commercializes vaccines for the prevention of life-threating diseases. The company develops its products using poxvirus-based technology platforms including modified vaccinia Ankara –Bavarian Nordic (MVA-BN). The company’s marketed products include JYNNEOS for smallpox and monkeypox; Encepur for tick-borne encephalitis; MVABEA for ebola; and Rabipur/RabAvert for rabbies. Its pipeline products are intended for the treatment of smallpox, respiratory syncytial virus, COVID-19, HER2- and brachyury-expressing cancers and Ebola infections. Bavarian Nordic has collaboration with the US government and various institutes, to develop its product candidates for the treatment of cancer and infectious diseases. It has a presence in the US, Denmark, Switzerland and Germany. Bavarian Nordic is headquartered in Hellerup, Denmark.

Quick View Vaccine to Target Brachyury for Oncology LOA Data

Report Segments
  • Innovator
Drug Name
  • Vaccine to Target Brachyury for Oncology
Administration Pathway
  • Intratumor
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.